Incyte’s (INCY) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Incyte (NASDAQ:INCY) in a research note published on Wednesday,Benzinga reports. HC Wainwright currently has a $135.00 target price on the biopharmaceutical company’s stock.

Several other research analysts have also weighed in on the stock. Barclays upped their target price on shares of Incyte from $115.00 to $116.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 4th. The Goldman Sachs Group reissued a “neutral” rating and set a $90.00 price target on shares of Incyte in a research note on Thursday, January 8th. Truist Financial set a $103.00 price objective on Incyte in a report on Wednesday, December 24th. Stifel Nicolaus set a $119.00 price objective on shares of Incyte in a research note on Monday, January 5th. Finally, Piper Sandler raised their target price on shares of Incyte from $102.00 to $110.00 and gave the company an “overweight” rating in a report on Friday, February 6th. Nine research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $103.94.

Incyte Trading Down 1.2%

Shares of INCY stock opened at $98.84 on Wednesday. The business’s fifty day moving average price is $101.75 and its 200 day moving average price is $93.81. The firm has a market capitalization of $19.40 billion, a PE ratio of 15.42, a P/E/G ratio of 0.60 and a beta of 0.82. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.23 and a quick ratio of 3.13. Incyte has a 1-year low of $53.56 and a 1-year high of $112.29.

Incyte (NASDAQ:INCY) last issued its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.80 EPS for the quarter, missing the consensus estimate of $1.96 by ($0.16). The company had revenue of $1.51 billion for the quarter, compared to analysts’ expectations of $1.35 billion. Incyte had a return on equity of 26.34% and a net margin of 25.03%.Incyte’s revenue for the quarter was up 27.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.43 earnings per share. As a group, sell-side analysts forecast that Incyte will post 4.86 EPS for the current fiscal year.

Insider Activity

In other news, EVP Steven H. Stein sold 20,105 shares of the business’s stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $102.51, for a total value of $2,060,963.55. Following the completion of the transaction, the executive vice president owned 63,129 shares of the company’s stock, valued at $6,471,353.79. The trade was a 24.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Mohamed Khairie Issa sold 10,856 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $109.07, for a total transaction of $1,184,063.92. Following the transaction, the executive vice president directly owned 66,132 shares in the company, valued at $7,213,017.24. The trade was a 14.10% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 95,225 shares of company stock valued at $9,519,745. 17.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Incyte

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Arrowstreet Capital Limited Partnership boosted its stake in Incyte by 701.8% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 2,730,648 shares of the biopharmaceutical company’s stock worth $185,957,000 after buying an additional 2,390,084 shares during the last quarter. AQR Capital Management LLC lifted its holdings in shares of Incyte by 21.8% during the 2nd quarter. AQR Capital Management LLC now owns 8,201,455 shares of the biopharmaceutical company’s stock worth $558,519,000 after acquiring an additional 1,465,286 shares during the period. Norges Bank acquired a new stake in shares of Incyte in the second quarter worth approximately $96,776,000. Pacer Advisors Inc. grew its holdings in Incyte by 8,091.6% in the third quarter. Pacer Advisors Inc. now owns 1,248,642 shares of the biopharmaceutical company’s stock valued at $105,897,000 after purchasing an additional 1,233,399 shares during the period. Finally, Marshall Wace LLP purchased a new stake in Incyte in the second quarter valued at approximately $82,485,000. Hedge funds and other institutional investors own 96.97% of the company’s stock.

Key Headlines Impacting Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Management laid out a 10–13% revenue growth target for 2026 and emphasized pipeline expansion and upcoming product launches, which supports medium‑term revenue upside if clinical readouts and launches progress as planned. Article Title
• Positive Sentiment: Q4 product sales topped expectations (Jakafi and Opzelura contributed to a ~28% revenue jump), showing demand strength that supports near-term cash flow. Article Title
• Positive Sentiment: HC Wainwright reiterated a Buy and $135 target (and other bullish research notes highlighted long‑term revenue durability), which could attract buyers looking past the guidance miss. Article Title
• Neutral Sentiment: Company provided an earnings‑call transcript and slide deck; management framed growth “beyond Jakafi,” useful for investors parsing product mix and timing of launches. Article Title
• Neutral Sentiment: Incyte completed a real‑estate sale (Wilmington Bracebridge towers), a non‑core cash/asset move that modestly improves balance sheet flexibility but is unlikely to materially alter operating outlook. Article Title
• Neutral Sentiment: Analyst coverage is mixed/pragmatic — some trims to targets but others reaffirm buys; expect continued analyst debate while Jakafi patent timing and Opzelura trajectory become clearer. Article Title
• Negative Sentiment: EPS missed estimates (Q4 EPS $1.80 vs. ~$1.96 expected) and management issued a softer 2026 revenue forecast; that guidance miss is the primary driver of today’s pullback. Article Title
• Negative Sentiment: Royal Bank of Canada lowered its price target (to $92) and commentary flagged downside vs. current levels, which may weigh on sentiment until guidance clarity improves. Article Title
• Negative Sentiment: Regulatory risk: emerging “Most Favored Nation” drug‑pricing policies and looming Jakafi patent expiry remain material downside risks to margin and revenue durability. Article Title

About Incyte

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.